Tenaya Therapeutics, Inc. (TNYA)
NASDAQ: TNYA · Real-Time Price · USD
0.7611
+0.1011 (15.32%)
Jan 29, 2026, 10:56 AM EST - Market open
Tenaya Therapeutics Employees
Tenaya Therapeutics had 97 employees as of December 31, 2024. The number of employees decreased by 43 or -30.71% compared to the previous year.
Employees
97
Change (1Y)
-43
Growth (1Y)
-30.71%
Revenue / Employee
n/a
Profits / Employee
-$971,732
Market Cap
164.78M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 97 | -43 | -30.71% |
| Dec 31, 2023 | 140 | -1 | -0.71% |
| Dec 31, 2022 | 141 | 35 | 33.02% |
| Sep 30, 2022 | 140 | 40 | 40.00% |
| Jun 30, 2022 | 135 | 50 | 58.82% |
| Mar 31, 2022 | 125 | 50 | 66.67% |
| Dec 31, 2021 | 106 | 31 | 41.33% |
| Sep 30, 2021 | 100 | 25 | 33.33% |
| Jun 30, 2021 | 85 | - | - |
| Mar 31, 2021 | 75 | - | - |
| Dec 31, 2020 | 75 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fate Therapeutics | 181 |
| Molecular Partners AG | 159 |
| Caribou Biosciences | 147 |
| Vaxart | 105 |
| Connect Biopharma Holdings | 62 |
| Sol-Gel Technologies | 34 |
| Elicio Therapeutics | 32 |
| Black Diamond Therapeutics | 24 |
TNYA News
- 20 days ago - Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones - GlobeNewsWire
- 6 weeks ago - Tenaya Stock Plunges After $60 Million Equity Offering - Benzinga
- 6 weeks ago - Tenaya Therapeutics Announces Pricing of Public Offering - GlobeNewsWire
- 6 weeks ago - Tenaya Therapeutics, Inc. (TNYA) Discusses Initial Data From RIDGE-1 Phase Ib/II Trial of TN-401 Gene Therapy for ARVC Prepared Remarks Transcript - Seeking Alpha
- 6 weeks ago - Tenaya Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 6 weeks ago - Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC - GlobeNewsWire
- 6 weeks ago - Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy - GlobeNewsWire
- 2 months ago - Tenaya Therapeutics, Inc. (TNYA) Shareholder/Analyst Call Transcript - Seeking Alpha